Sep 15 2010

Christine O’Donnell, Rand Paul and the Primaries: Are They the Right Stuff?

NEW YORK — Christine O’Donnell’s dramatic come-from-nowhere victory in the Delaware Senate Republican primary could easily be interpreted as proof of the potency of a Sarah Palin endorsement and a Tea Party imprimatur. But it also can be viewed as a repudiation her establishment opponent, 71-year-old nine-term Congressman Michael Castle, perhaps the last old-fashioned GOP [...]


Sep 11 2010

Fox News, CNN Made Right Decision on Koran Coverage

After Fox News announced it would not cover the burning of Korans, I started wondering whether or not other news networks would follow its lead (should the event actually take place). TV Newser asked several outlets about it, and received the following responses: ABC News says that it will have people there to cover the [...]


Sep 3 2010

Koch Brothers Donate to Charity as well as ‘Right Wing Causes’

The New Yorker’s Jane Mayer recently wrote a profile of billionaires Charles and David Koch of Koch Industries called “Covert Operations,” in which she details how the brothers are “waging war against Obama.” The piece also raises concerns about their business practices. As Mayer writes, “The Kochs are longtime libertarians who believe in drastically lower [...]


Sep 1 2010

From a Lefty: Five Things the Right Is Doing Right

For nearly two years, the Democrats have controlled the House, the Senate, the presidency and two new judicial appointments to the Supreme Court. So why does it feel like the Democrats lost in 2008? I think it’s because the Democrats have turned losing into an art form. You know how they say a good dancer [...]


Sep 1 2010

What Price Is Right for Genzyme?

The chief executive of Genzyme, Henri A. Termeer, on Tuesday appeared to soften his tone about a possible sale, a day after his company rejected a $69-a-share offer from Sanofi-Aventis. In an interview with The Boston Globe, Mr. Termeer acknoweldged that Genzyme was now in play even as he reiterated that Sanofi’s price undervalued the [...]


Sep 1 2010

What Price Is Right for Genzyme?

The chief executive of Genzyme, Henri A. Termeer, on Tuesday appeared to soften his tone about a possible sale, a day after his company rejected a $69-a-share offer from Sanofi-Aventis. In an interview with The Boston Globe, Mr. Termeer acknoweldged that Genzyme was now in play even as he reiterated that Sanofi’s price undervalued the [...]